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Abstract.  Acute  promyelocytic  leukemia  (APL)  is  the  subtype  of  acute  myeloid  leukemia 
characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding 
tendency and the presence of the chromosomal translocation t(15;17) or variants. APL, the most 
fatal type of leukemia two decades ago, is highly curable with current treatment strategies. There is 
evidence that the incidence of APL varies across ethnic groups and that geneti
in the etiology of APL. And there are some difference betwe
limited  data  of  children  available  in  many  developing  countries  suggest  that  the  rate  of  early 
mortality is high and that long-term 
chemotherapy, relapse and treatment abandonment are among the main cause of treatment failure 
in APL children as well in adults.
described in general. 
Here we describe the epidemiology and treatment of APL in children in China. In addition, we 
review the results of a survey of its clinical manifestations and outcome in China.
Epidemiology of APL.
Demographics.  The  real  incidence  of  APL  is  not 
known.  The  lack  of  population-based  registries  in 
China made it difficult to determine the real incidence 
of APL. The incidence of APL was estimated on the 
basis  of  its  relative  frequency  among  other  AML 
subtypes in large clinical trials. The Hematology and 
Blood  Diseases  Hospital  of  Chinese  Academy  of 
Medical Sciences and Peking Union Medical College 
has  provided  information  about  child  APL.
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Acute  promyelocytic  leukemia  (APL)  is  the  subtype  of  acute  myeloid  leukemia 
characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding 
esence of the chromosomal translocation t(15;17) or variants. APL, the most 
fatal type of leukemia two decades ago, is highly curable with current treatment strategies. There is 
evidence that the incidence of APL varies across ethnic groups and that geneti
in the etiology of APL. And there are some difference between children and adults in APL.
limited  data  of  children  available  in  many  developing  countries  suggest  that  the  rate  of  early 
term survival is poor. Death from bleeding and infection during 
chemotherapy, relapse and treatment abandonment are among the main cause of treatment failure 
in APL children as well in adults.
2 The status of children APL treatment in China has not been 
Here we describe the epidemiology and treatment of APL in children in China. In addition, we 
review the results of a survey of its clinical manifestations and outcome in China.
The  real  incidence  of  APL  is  not 
based  registries  in 
China made it difficult to determine the real incidence 
of APL. The incidence of APL was estimated on the 
of  its  relative  frequency  among  other  AML 
subtypes in large clinical trials. The Hematology and 
Blood  Diseases  Hospital  of  Chinese  Academy  of 
Medical Sciences and Peking Union Medical College 
has  provided  information  about  child  APL.
4 In  this 
registry, 51(31.6%) of the 141 cases of AML registered 
between 1996 and 2004. In the Children's hospital of 
Zhejiang  University  School  of  Medicine  registry, 
49(26.5%) of the 185 cases of AML registered between 
1997  and  2005.
5 The  percentage  of  APL  could  be 
higher in children  than in adults
These data is somewhat higher than the 5% to 13% 
reported  by  many  large  clinical  trials  and  single 
institutions in the US.
7 Also of note, this incidence is 
similar  to  Latin American  background patients.
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Acute  promyelocytic  leukemia  (APL)  is  the  subtype  of  acute  myeloid  leukemia 
characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding 
esence of the chromosomal translocation t(15;17) or variants. APL, the most 
fatal type of leukemia two decades ago, is highly curable with current treatment strategies. There is 
evidence that the incidence of APL varies across ethnic groups and that genetic factors play a role 
en children and adults in APL.
1-3 The 
limited  data  of  children  available  in  many  developing  countries  suggest  that  the  rate  of  early 
survival is poor. Death from bleeding and infection during 
chemotherapy, relapse and treatment abandonment are among the main cause of treatment failure 
The status of children APL treatment in China has not been 
Here we describe the epidemiology and treatment of APL in children in China. In addition, we 
review the results of a survey of its clinical manifestations and outcome in China.
31.6%) of the 141 cases of AML registered 
between 1996 and 2004. In the Children's hospital of 
Zhejiang  University  School  of  Medicine  registry, 
49(26.5%) of the 185 cases of AML registered between 
The  percentage  of  APL  could  be 
ildren  than in adults.
6
These data is somewhat higher than the 5% to 13% 
reported  by  many  large  clinical  trials  and  single 
Also of note, this incidence is 
similar  to  Latin American  background patients.
7 The Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
difference  of  ethnicity may  be  the  explanation.  In 
addition, admission bias have to be considered for the 
favorable  outcome  in  APL.  Population-based  cancer 
registries  is  needed  to  confirm  the  real  incidence  of 
APL. 
Other factors. Most of people in China is Han descent. 
So there is no data about epidemiology feature of APL 
in different ethnic groups. 
Diagnosis  and  Treatment  of  Acute  Promyelocytic 
Leukemia.
Diagnosis  of  APL.  The  French-American-British 
(FAB) classification recognizes two main morphologic 
APL  subtypes,  including  a  more  frequent 
hypergranular  form  (M3)  featured  by  abnormal 
dysplastic  promyelocytes  with  abundant  cytoplasmic 
granules  and  Auer  bodies,  and  a  less  frequent 
microgranular  form  characterized  by  abnormal 
promyelocytes with minimal cytoplasmic granulation, 
reniform  or  bilobed  nuclei,  and  can  be  confused 
morphologically  with  monocytic  subtypes  of  AML.
3
There is no data about the rate of hypergranular form 
and microgranular form in the studies in china. Zhang 
et  al  described  one  patients  who  was  diagnosed  as 
acute monocytic leukemia initially died at 4 days after 
treated with cytarabine.
8
APL immunophenotype is characterized by frequent 
expression of CD13 and CD33and rare expression of 
HLA-DR, CD34, CD10, CD7, CD11b, and CD14.
3
At  the  genetic  level,  APL  is    for  the  most 
characterized  by  a  unique  reciprocal  chromosome 
translocation t(15;17)(q22;q11-12), leading to a fusion 
between  the  promyelocytic  (PML)  gene  on 
chromosome  15  and  the  retinoic  acid  receptor-α 
(RARa)  gene  on  chromosome  17.  In  our  study
8
including 65 children cytogenetics  was performed in 
47  patients,  20  (42%)  patients  had  the 
t(15;17)(q22;q11-12),  10  (21%)  had  additional 
cytogenetic abnormalities to t(15;17)(q22;q11-12), 14 
(30%)  had a normal pattern, in  3   other cytogenetic 
abnormalities were present. 
The  additive  chromosomal  changes  was  not 
associated with a different outcome.
Most  of  these  patients  was  diagnosed  by  the 
presence of the fusion protein PML/RARa detected by 
polymerase chain reaction. In China, minimal residual 
disease (MRD) monitoring based on the detection of 
PML/RARa transcripts was mainly performed utilizing 
the  reverse  transcription  polymerase  chain  reaction 
(RT-PCR). Some of the hospitals can monitor MRD by 
real-time  quantitative  PCR  (RQ-PCR).  In  our  study, 
the  rate  of  bcr1,  bcr2  and  bcr3  PML/RARa subtype 
mRNA is 71.8%, 7.7% and 20.5%, respectively. And 
we analyzed the prognostic value of the standardized 
PML/RARa  RQ-PCR  assay in  children  with  newly 
diagnosed  APL  children.  At  the  end  of  the  third 
consolidation course, no patient was RQ-PCR-positive 
except for one who relapsed. Our results indicated that 
patients with a negative RQ-PCR result after induction 
were correlated with a lower probability of relapse.
9
Treatment  of  APL.  Optimal  management  of  APL 
requires prompt diagnosis and immediate initiation of 
treatment. Before the late 1980s, APL was treated the 
same  as  other  AML  subtypes.  Although  in  the 
developed country, the remission rate was much lower 
than 70%.
10,11 The discovery of the clinical efficacy of 
all-trans  retinoic  acid  (ATRA)  by  Chinese 
hematologists  turned  a  new  page  in  the  history  of 
leukemia  therapy.
12 In  the  mid-1990s,  the  first 
controlled  clinical  trial  of  arsenic  trioxide  (ATO) 
further improved the clinical outcome of refractory or 
relapsed APL.
13
Table  1 lists  selected  clinical,  laboratory,  and 
outcome data from children with APL obtained from 
China  which  had  been  published  recently.
5,7,14-18
Cytogenetic  and molecular  diagnosis  of  APL  was 
confirmed  in  most  of  the  centers.  Conventional  RT-
PCR had been widely used for therapeutic monitoring 
of APL. ATRA was used in the management of most 
of  these  centers,  but  in  harbin,  19  patients  received 
ATO without ATRA. The median age was around 9 
years. There was a predominance of boys (M:F ratio, 
1.06-2.5). The median white blood cell (WBC) count at 
diagnosis varied from 3.46×10
9/L to 10.5×10
9/L, and 
the  median  platelet  count  from  21×10
9/L  to 
36.5×10
9/L. Rate of complete remission (CR) ranged 
from  85.7%  in  Shen  yang  to  95.1%  in  Zhe  jiang. 
Abandonment or refusal of treatment was documented 
in  21  cases.  Also  of  note,  the  abandonment  rate 
decreased from 31.25% (5/16) to none after 2005 in 
Guang  zhou.
15 The  improvement  may  be  due  to  the 
better economic status and improved financial support 
recently.  Except  for  the  study  with  high  rate  of 
abandonment in Guang zhou, most of the other studies 
suggested the similar outcomes when compared with 
the other large series of children APL groups treated 
with  ATRA  and  chemotherapy.
19 The  outcome  of 
children  with  APL  in  China  comparatively  better  in 
developing countries.
2 Treatment with ATRA as soon 
as  possible  after  morphologic  diagnosis  in  the  bone 
marrow,  with  experience  in  the  supportive  care  and 
management of complication, and added ATO in the 
salvage treatment may be the explanation. 
As  described  in  table  1,  the  relapse  rate  is 
difference among different studies.
5,7,13-17 The patients 
who  relapsed  will  be  treated  with  ATO±ATRA. 
Occasionally,  the  relapsed  patients  will  give  up 
treatment.Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Selected clinical, laboratory, and outcome features of children with acute promyelocytic leukemia (APL) in China. 
Special  treatment  issues  for  Children  with  APL.  A 
special  note  is  necessary  for  the  risk  of 
cardiomyopathy,  a  real  threat  for  children  with  APL 
treated  with  regimens  that  utilize  high  doses  of 
anthracyclines.  Van  Dalen  et  al  suggest  the  risk  of 
developing clinical heart failure was dose-dependent, 
increasing from 0% for 150 mg/m
2 of anthracyclines 
up to 14.3% for 600 mg/m
2.
20 In our experience there 
was  one  5-year-old  boy  who  developed  severe 
congestive  heart  failure  when  the  total  dose  of 
anthracycline  was  reach  to  530  mg/m
2 body  surface 
due to molecular relapse.
21 However, no long-term data 
about cardiotoxicity of anthracycline can be described 
in China so far. 
Another issue of special importance in children with 
APL  is  the  difficulty  in  swallowing  the  capsule  of 
ATRA. A novel intravenous liposomal formulation of 
ATRA  has  been  shown  to  be  effective  in  inducing 
CR.
22 However,  this  form  is  not  commercially 
available yet. Then ATO may be considered for these 
patients.
Current  Situation  in  China.  Several  years  ago, 
financial support from the government was lack. Most 
families did not have medical insurance. So they could 
not afford the costly medical care. Recently, financial 
support  from  the  society  (such  as  China  Red  Cross 
foundation:  www.crcf.org.cn/xts/index.asp)  and  the 
government  (www.gov.cn/zwgk/2010-
06/10/content_1624580.htm)  had  increased  the 
coverage  of  medical  insurance  to  ensure  that  most 
families  can  afford  the  treatment  costs.  Since  2009, 
more than 3,000 children with leukemia received the 
financial support from the China Red Cross foundation. 
However, there are still more patients needs financial 
support  so  as  to  be  treated  regularly.  In  addition, 
setting  up  the  population-based  cancer  registries  in 
China is necessary to obtain data with sufficient quality 
for international comparison. 
Although  the  outcome  of  children  with  APL  in 
China is improved, we hope to establish a relationship 
with hematologists/oncologists in the world to promote 
international communication.
Authors (et al) Li Zhang
8 Jing 
Chen
14 Xue-Qun Luo
15 Xiao-Jun Xu
5 Jin Zhou
16 Hong 
Wang
17 Li Zhang
18
City Tianjin Shanghai Guangzhou Zhejiang Harbin Shenyang Tianjin
Year 2008 2008  2009  2010 2010  2010 2011
Period(Year/Month) 1999/1-
2005/12 
1998/7-
2006/5
1999/12-
2004/12
2005/1-
2008/1
1997/1-
2005/12
2001/8-
2007/1
2000/1-
2009/1
1999/1-
2003/12
Diagnosis methods
Chromosome/RT-
PCR/other
47/50/6  21/21/14  NA  NA NA 11/16/0  10/18/7 7/30/0 
No, patients 65  35 16‡ 14 41§ 19¶ 35 37
Age,median(range) 13
(2-18)
9.3
(0.4-15)
9
(0.5-15)
9.9
(1.5-13.8) 4-15  NA 2-14
Sex,male/femal (ratio) 36/26
(1.38)  21/14(1.5)
10/6
(1.66) 
10/4
(2.5)
22/19
(1.15)
11/8
(1.38)
22/13
(1.69)
19/18
(1.06)
WBC×10
9/L,median(ra
nge)
3.46
(0.9-580) 
10.5
(0.9-47.8)
8
(1-143)
7
(2-187)
5.2
(2.0-221.8)
4.8
(1.0-89.6) NA 1.12-580
    WBC≥10×10
9/L(%) 17(26.2)  11(33.3) NA  NA NA 7  NA 10
    WBC<10×10
9/L (%) 48(73.8) 22(66.6) NA  NA NA 12 NA 27
PLT×10
9/L,median
(range)
23.0
(4-153)   NA  21
(8-267) 
26
(9-128)
35
(1.5-216)
36.5
(10-102) NA 6-153
    PLT≥40×10
9/L 19(29.2) NA  NA NA 8 NA NA
    PLT<40×10
9/L 46(70.8) NA  NA NA 11 NA NA
Induction treatment   ATRA±ATO ATRA+C
T
ATRA+C
T
ATRA+C
T ATRA ATO ATO±AT
RA
ATRA±AT
O 
    CR (No.) (%) 59(90.8) 33(94.3) 9(90) 13(92.9) 39(95.1) 17(89.5) 30(85.7) 35(94.6)
    Early death (No.)(%)  6(9.2)* 2(5.7) 1(10) 1(7.1) 2(4.9) 2(10.5) 3(8.6)  2(5.4)
    Other 2(5.7)**
Consolidation treatment CT CT† CT† CT CT† ATO CT CT
Follow-up (months) 38(1-93) 49(4-103) 69(28-135) 53(23-76) 10-108 76(2-129)
Event-free survival (%) 77.5%
(5-year)
73.4%
(7-year)
37.5%
(3.5year)
79.6%
(3.5year)
63.5%
(7-year)
72.7%
(5-year)
78.3%
(5-year)
79.2%
(5-year)
Disease-free 
survival(%)
85.4%
(5-year)
73.4%
(7-year)
83.7%
(5-year)
Overall survival (%) 88.9%
(5-year)
91.2%
(7-year)
66.9%
(7-year)
83.9%
(5-year)
82.7%
(5-year)
91.5%
(5-year)Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
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